Ned Pagliarulo Lead Editor Courtesy of US Food and Drug Administration Food and Drug Administration scientists have major concerns with an application filed by biotechnology company BrainStorm Cell Therapeutics for approval of a personalized stem cell treatment for amyotrophic lateral sclerosis documents posted online Monday show